differences in disease-free survival were observed for those patients with adnexal metastases versus those with no adnexal disease ( p = 0.002 ) , those with estrogen receptor-rich versus estrogen receptor-poor tumors , outer third myometrial invasion ( p = 0.002 ) , and patients with clinical stage i versus clinical stage ii disease ( p = 0.03 ) .
C0027651
tumors
C0012634
disease